Applied Molecular Shares Tumble After Disappointing Data From Mid-Stage Ulcerative Colitis Study
Applied Molecular Transport Inc (NASDAQ: AMTI) has
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Applied Molecular Transport Inc
Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs
Applied Molecular Transport Inc (NASDAQ:AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development. It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis. Applied Molecular is evaluating the next steps for AMT-126, which recently demonstrated safety and tolerability in…
Benzinga ·
Applied Molecular's AMT-101 Shows Favorable Clinical Activity, Safety Profile In Inflammatory Bowel Disease
Applied Molecular Transport Inc (NASDAQ:AMTI) announced Phase 2 topline results from the FILLMORE monotherapy trial for AMT-101 in chronic pouchitis. Pouchitis is inflammation in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases. The trial demonstrated that 36.4% (8/22) of patients achieved stool frequency response. Rapid…
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
